Αρχική World News Access to Cancer Medicines and Clinical Trials Show Stark Variations Across Europe...

Access to Cancer Medicines and Clinical Trials Show Stark Variations Across Europe [ESMO Press Release]

LBA66_PR – Disparities in access to oncology clinical trials in Europe in the period 2009-2019

A. Carneiro1, T.M.S. Amaral2, M. Brandao3, M. Scheffler4, K. Bol5, R. Ferrara6, M. Jalving7, G. Lo Russo8, I. Marquez-Rodas9, A. Matikas10, L. Mezquita11, G. Morgan12, C.E. Onesti13, S. Pilotto14, E. Saloustros15, D. Trapani16
1Department of Clinical Sciences Lund, Oncology, Lund University, Skane University Hospital, Lund, Sweden, 2Dermatooncology Center, University Hospital Tubingen, Tuebingen, PT, Germany, 3Clinical Trial Support Unit, Institute Jules Bordet, Brussels, Belgium, 4Lung Cancer Group Cologne, Department I of Internal Medicine, Uniklinik Köln, Cologne, Germany, 5Medical Oncology Department, Herlev Hospital – National Center for Cancer Immune Therapy, Herlev, Denmark, 6Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy, 7Department of Medical Oncology, University Medical Center Groningen, Groningen, Netherlands, 8Dipartimento Oncologia Toraco-Polmonare, Istituto Nazionale dei Tumori di Milano – Fondazione IRCCS, Milan, Italy, 9Medical Oncology, Hospital General Universitario Gregorio Marañon – Fundación Investigación Biomedica, Madrid, Spain, 10Oncology-Pathology Department, Karolinska University Hospital-Solna, Stockholm, Sweden, 11Medical Oncology Department, Hospital Clinic y Provincial de Barcelona, Barcelona, Spain, 12Oncology, Skane University Hospital, Lund, Sweden, 13Medical Oncology department, Centre Hospitalier Universitaire Sart Tilman, Liège, Belgium, 14Section of Oncology, Department of Medicine, University of Verona School of Medicine and Verona University Hospital Trust, Verona, Italy, 15Department of Oncology, University Hospital of Larissa, Larissa, Greece, 16IRCCS, Istituto Europeo di Oncologia, Milan, Italy

Background: Clinical trials are essential for advancing cancer treatment. Yet, there is limited data on their distribution and access in Europe. To ascertain the extent of potential inequalities in access to clinical trials in Europe, we compared their distribution among European countries.

Methods: The Clinicaltrials.gov database was searched for interventional clinical trials in adults with neoplasms. Available data from phase I-III trials between 06/2009 to 06/2019 in Europe were retrieved. We considered the number of clinical trials registered in each country and one “trial-entry” was defined as one trial/country.

Results: In total, 18454 trial-entries were identified, of which 12% were phase I, 10% phase I/II, 32% phase II, 2% phase II/III and 44% phase III; 74% were industry-sponsored, 15% were academic and 11% were an academic/industry partnership. The number of trials per country varied from 2.48 in Central/Eastern Europe to 5.33/100 000 inhabitants in Northern Europe. The proportion of phase I-II trials was higher in the Southern and Western regions (13-15%) compared to Central/Eastern and Northern regions (4-9%). The number of trial-entries/100 000 inhabitants/country ranged from 0.14 (Albania) to 10.7 (Belgium). Between 2010 and 2018, the total number of trials per country in Europe increased by 33%. The increase in early-phase trials was larger (phase I-II, 61%) than in late-phase trials (phase II-III, 7%). Portugal, Ireland, Finland, Greece and Norway registered the largest percentage increase in early-phase trials, while Ireland, Spain, Norway, Italy and Belgium led the largest percentage increase in late-phase trials. Five countries dominated in terms of an increase in the absolute number of total trial-entries in both early- and late-phase trials: Spain (90/40), France (45/16), UK (45/13), Italy (38/19) and Belgium (35/12). During this period there was no significant variation in the distribution of industry and academic sponsored trials but an increase in industry/academic partnerships was observed (≈ 8%).

Conclusions: The number of clinical trials varies greatly among European regions resulting in potential asymmetries in patients’ access to clinical trials. The disparities in access to oncology trials need to be addressed by all the stakeholders.

Legal entity responsible for the study: The authors

Funding: Has not received any funding

Disclosure: T.M.S. Amaral: Honoraria (self), Travel/Accommodation/Expenses: Novartis; Honoraria (self), Travel/Accommodation/Expenses: BMS; Honoraria (self): Pierre Fabre; Honoraria (self): CeCaVa.
M. Brandao: Speaker Bureau/Expert testimony, Travel/Accommodation/Expenses: Roche/GNE.
M. Scheffler: Advisory/Consultancy, Speaker Bureau/Expert testimony: Boehringer Ingelheim, AMGEN, AstraZeneca, BMS, Roche, Pfizer, Takeda; Research grant/Funding (self): AMGEN, Dracen.
R. Ferrara: Advisory/Consultancy: MSD.
M. Jalving: Advisory/Consultancy: MERCK, BMS, NOVARTIS, PIERRE FABRE, TESARO, ASTRA ZENECA; Research grant/Funding (self): BMS, ABBVIE, MERCK, CRISTAL THERAPEUTICS.
G. Lo Russo: Advisory/Consultancy: MSD, BMS, ASTRAZENECA; Travel/Accommodation/Expenses: BMS, ROCHE.
I. Marquez-Rodas: Advisory/Consultancy: BMS, MSD, NOVARTIS, ROCHE, PIERRE FABRE, AMGEN, ASTRA ZENECA, REGENERON, SANOFI, HIGHLIGHT THERAPEUTICS, INCYTE, GSK.
L. Mezquita: Research grant/Funding (self): Bristol-Myers Squibb, Boehringer Ingelheim; Non-remunerated activity/ies, Lectures and educational activities: Bristol-Myers Squibb, Tecnofarma, AstraZeneca, Roche; Advisory/Consultancy: Roche Diagnostics, Roche; Travel/Accommodation/Expenses: Bristol-Myers Squibb, Roche; Research grant/Funding (self), International Mentorship Program : AstraZeneca.
S. Pilotto: Advisory/Consultancy, Speaker Bureau/Expert testimony: Astra-Zeneca, Eli-Lilly, BMS, Boehringer Ingelheim, MSD and Roche.
E. Saloustros: Advisory/Consultancy: Pfizer, AstraZeneca, Roche; Speaker Bureau/Expert testimony: Pfizer, AstraZeneca, Roche, Amgen, BMS.
All other authors have declared no conflicts of interest.

Source

NEWSLETTER

Συμπληρώστε το email σας για να λαμβάνετε τις σημαντικότερες ειδήσεις από το ogkologos.com

Βρείτε μας

2,449ΥποστηρικτέςΚάντε Like
57ΑκόλουθοιΑκολουθήστε

Διαβαστε Επίσης

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ)

ΕΞΕΛΙΞΕΙΣ ΣΤΗ ΘΕΡΑΠΕΙΑ ΤΟΥ ΜΗ-ΜΙΚΡΟΚΥΤΤΑΡΙΚΟΥ ΚΑΡΚΙΝΟΥ ΤΟΥ ΠΝΕΥΜΟΝΑ (ΜΜΚΠ) Γράφει ο Δρ Παπαδούρης Σάββας, Παθόλογος-Ογκολόγος   Ο ΜΜΚΠ βρίσκεται αναλογικά στο 80% και πλέον του συνολικού...

Διατρέχουν όντως οι καρκινοπαθείς μεγαλύτερο κίνδυνο λόγω κοροναϊού;

Σε πρακτικό επίπεδο, τα δεδομένα των σχετικών μελετών υποδηλώνουν ότι η χημειοθεραπεία ή οι άλλες αντι-νεοπλασματικές θεραπείες δεν αυξάνουν σημαντικά τον κίνδυνο θνησιμότητας από...

FDA: Η ακτινοβολία των smartphones δεν προκαλεί καρκίνο

Σε μια νέα έκθεσή της, η Υπηρεσία Τροφίμων και Φαρμάκων (FDA) των ΗΠΑ αναφέρει ότι επανεξέτασε τις σχετικές επιστημονικές έρευνες που δημοσιεύθηκαν τα τελευταία...

Νέα ανακάλυψη, νέα ελπίδα για τον καρκίνο

Ένα νεοανακαλυφθέν τμήμα του ανοσοποιητικού μας συστήματος θα μπορούσε να αξιοποιηθεί για την αντιμετώπιση όλων των ειδών καρκίνου, σύμφωνα με επιστήμονες του πανεπιστημίου Cardiff...

Καρκίνος: Ευεργετική για τους καρκινοπαθείς η άσκηση

Σημαντικά ωφέλη προσφέρει η άσκηση, ακόμη και σε ασθενείς με καρκίνο. Οι περισσότεροι ασθενείς αγνοούν τα οφέλη που μπορεί να έχει γι’ αυτούς η συχνή...

Prostate Cancer

The article is provided by Scientific Communications Officer of NIPD Genetics, Ms Marina Charitou (MSc) Prostate Cancer Awareness Prostate cancer is the second most common cancer...
- Advertisment -

Ροή Ειδήσεων

EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

Easy Meals at Home

Our theme this week is delicious, easy to make, at home meals. These recipes minimize your cook time and maximize your food enjoyment. Ingredients 8...

This Saturday: National Prescription Drug Take-Back Day

Have you taken a look at your medicine cabinet lately? Aside from cotton swabs, mouthwash and makeup remover, are there old, outdated prescription drugs...

How People With Cancer Can Benefit From Online Therapy

Tanya J. Peterson, MS, is credentialed with the National Board of Certified Counselors. She is a regular contributor to the mental health website, Choosing...

EMA Recommends Granting a Conditional Marketing Authorisation for Autologous Anti-CD19-Transduced CD3+ Cells

On 15 October 2020, the European Medicines Agency’s (EMA’s) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting...

New Treatment Helps Survivors Regain Sensation After Breast Cancer

When NBC’s Kristen Dahlgren was diagnosed with breast cancer, she didn’t think much about the lack of sensation that her mastectomy would likely leave...